After tumor progression with EGFR TKI therapy and PBC in patients with EGFRm NSCLC, HER3‐DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. This evidence concerns the gene EGFR and non-small cell lung carcinoma.